Hengrui Pursues Innovation Through New $100m US Spinoff
China’s Jiangsu Hengrui Medicine is accelerating its move towards innovation by increasing investment and partnerships, as part of a strategy to shift its focus away from its traditional generic business. It is now providing substantial funding to a new US-based spinoff aiming to develop oncology biologics and immunotherapies and to act as an innovation bridge between the US and China.
You may also be interested in...
Fosun Pharma and Shanghai Pharma have both officially denied their involvement in any bidding battle for German company Stada, although both Chinese firms make no secret of their international expansion ambitions and have been active deal makers in the past.
Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.
Alliances and expansion into international markets, helped by M&A, are seen by many growing and research-focused Chinese pharma companies as essential to their business development aspirations, although a recent industry forum in Changzhou also heard that such firms should keep a firm footing at home to become an attractive partner.